All News
Novel and Emerging Therapies in Psoriatic Arthritis
Recent advancements in targeted therapies, including selective inhibitors of key inflammatory pathways, offer promising outcomes for patients with active psoriatic arthritis (PsA). At ACR 2024, there have been further developments in novel therapies in PsA.
Read Article
⏩Lecture by Prof Takeuchi on Sjogren Syndrome. Anti-centromere ab is seen in 10% of primary Sjogren syndrome. more likely to have sclerodactyly. https://t.co/mVry2OaNmq @IRACON24Blr https://t.co/SZlWQDpx8B
Links:
Dr. Dinesh Khanna sclerodermaUM ( View Tweet)
New #OAC #BasicScience
This work by Shakya et al. found that basic calcium phosphate crystals are almost exclusively found in menisci from OA patients, while calcium pyrophosphate has similar prevalence in menisci from subjects with and without OA.
🔗 : https://t.co/PBaVQSspiE https://t.co/ivOOKVIX9b
Links:
Osteoarthritis and Cartilage Journals OACJournal ( View Tweet)
PsA Ultrasound Updates
Dr. Catherine Bakewell and Dr. Lihi Eder discuss updates on ultrasound in psoriatic arthritis at #ACR2024
https://t.co/XJOuKl8lCF https://t.co/XPMlf3sOnU
Dr. John Cush RheumNow ( View Tweet)
Day 1 Recap at #ACR24
Panelists Dr. Sheila Reyes, Dr. Adela Castro, Dr. Mike Putman and Dr. Jack Cush recap the most interesting abstracts and presentations they saw on day 1 of ACR 2024.
https://t.co/8M0WhOLETg https://t.co/hW5cgRiy6F
Dr. John Cush RheumNow ( View Tweet)
Improving fertility in women with RA
For women with rheumatoid arthritis (RA), the journey to motherhood brings unique challenges, such as longer times to conception and infertility rates twice as high as those without RA. Factors like high disease activity, regular use of… https://t.co/9QXgeB7ftB https://t.co/mVUabSdLNE
Dr. John Cush RheumNow ( View Tweet)
Sex related differences in PsA
Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA). Recently, there is new evidence that sex-related differences play a role not only in disease manifestations but also in efficacy and safety… https://t.co/9z9lorLtp0 https://t.co/XZRvm0S585
Dr. John Cush RheumNow ( View Tweet)
Playing it Safe with RA? JAK vs. TNF Debate
The ORAL surveillance trial raised safety concerns that the janus kinase inhibitor (JAKi) tofacitinib was associated with an increased incidence of cancer and major adverse cardiovascular events (MACE), compared to tumor necrosis… https://t.co/sUSdRKRxEF https://t.co/XcjOqGlLVX
Dr. John Cush RheumNow ( View Tweet)
Cognitive Impairment: The Hidden Burden in Lupus Care
Suppose you have a patient with SLE returning for follow-up. Their joint symptoms are well controlled. The kidneys—managed with a combination of biologic DMARD and mycophenolate—show no signs of active urinary sediment or… https://t.co/W8RO5aOaxj https://t.co/EF9P93hdPB
Dr. John Cush RheumNow ( View Tweet)
Assessing ASAS Criteria: CLASSIC Study Results
Dr. Adela Castro discusses abstract 0820, presented at #ACR24
https://t.co/rlzL8nAsiI https://t.co/7lbXWE3gdJ
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. Content is chosen by RheumNow & its facult.y
Dr. John Cush RheumNow ( View Tweet)
Cycling vs Switching after TNFi Failure in axSpA
Dr. Lihi Eder discusses abstract 0603, presented at #ACR24
https://t.co/qkDuutgqvv https://t.co/Agqopk6bh2
Dr. John Cush RheumNow ( View Tweet)
SELECT-GCA: Efficacy and Safety of Upadacitinib
Dr. Richard Conway discusses abstract 0770, presented at #ACR24
https://t.co/C9HZIMP9JK https://t.co/zVhFAfLBQe
Dr. John Cush RheumNow ( View Tweet)
Aging Gracefully in Managing Rheumatic Diseases
Dr. Mrinalini Dey and Dr. Elena Myasoedova review highlights from a session on aging presented at #ACR24.
https://t.co/tyT5d0JsEG https://t.co/szfDsSuWBx
Dr. John Cush RheumNow ( View Tweet)
NEW ONLINE POSTER: Safety of a JAKi presented at EULAR 2024!
View safety across 15,000 patient-years of data from 11 Phase 3 trials, including adult patients with RA, PsA, AS, and nr-axSpA. This poster is sponsored by AbbVie US Medical Affairs.
https://t.co/gIFWRqOGmD https://t.co/L0YttKihdf
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.
Dr. John Cush RheumNow ( View Tweet)
A new score to quantify GCA inflammation?
The treatment paradigm for Giant Cell Arteritis (GCA) has been a binary approach to the presence or absence of vasculitis. When GCA is present, we institute high doses of glucocorticoids for treatment of the inflammatory process. #ACR24… https://t.co/b5H7KOtZPC https://t.co/AvrwHcXI7r
Dr. John Cush RheumNow ( View Tweet)
Up-front Secukinumab in PsA?
We now have an absolute plethora of agents available for use in psoriatic arthritis (PsA). In contrast we have an almost complete lack of understanding of how best to optimise use of these agents – what is the right agent at the right time for the… https://t.co/OAQOutluPe https://t.co/gLfG840DBP
Dr. John Cush RheumNow ( View Tweet)
Gender Differences in SpA
#ACR24 provided its attendees with vast information about disease pathophysiology, diagnosis and treatment covering both clinical and basic sciences. One of the hot topics during the meeting was gender differences in SpA. Three abstracts presented… https://t.co/iEh0s3sIhc https://t.co/SRhz0Uwwwv
Dr. John Cush RheumNow ( View Tweet)
#ACR24 - Day 3 Report
Highlights from Day 3 at ACR24 included the plenary session presentation on Nipocalimab (previously reviewed), but the big highlight was the Lupus Nephritis guideline recommendations.
https://t.co/Dif4EUi30b https://t.co/4hfEJ1ef73
Dr. John Cush RheumNow ( View Tweet)